pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search

calendar

1,126 catalysts · 3,603 8k filing · 2,042 grant · 1,000 device adverse event · 955 approval · 696 device 510k · 585 earnings

★ save view↓export CSV
next 91 dayslessmore
MonWedFri
2026-08-24: 0 catalysts2026-08-25: 0 catalysts2026-08-26: 0 catalysts2026-08-27: 0 catalysts2026-08-28: 30 catalysts2026-08-29: 0 catalysts2026-08-30: 0 catalysts2026-08-31: 0 catalysts2026-09-01: 1 catalyst2026-09-02: 0 catalysts2026-09-03: 1 catalyst2026-09-04: 0 catalysts2026-09-05: 0 catalysts2026-09-06: 0 catalysts2026-09-07: 0 catalysts2026-09-08: 0 catalysts2026-09-09: 0 catalysts2026-09-10: 0 catalysts2026-09-11: 0 catalysts2026-09-12: 0 catalysts2026-09-13: 0 catalysts2026-09-14: 0 catalysts2026-09-15: 0 catalysts2026-09-16: 0 catalysts2026-09-17: 0 catalysts2026-09-18: 0 catalysts2026-09-19: 0 catalysts2026-09-20: 0 catalysts2026-09-21: 0 catalysts2026-09-22: 0 catalysts2026-09-23: 2 catalysts2026-09-24: 0 catalysts2026-09-25: 0 catalysts2026-09-26: 0 catalysts2026-09-27: 0 catalysts2026-09-28: 0 catalysts2026-09-29: 0 catalysts2026-09-30: 1 catalyst2026-10-01: 0 catalysts2026-10-02: 0 catalysts2026-10-03: 0 catalysts2026-10-04: 0 catalysts2026-10-05: 0 catalysts2026-10-06: 0 catalysts2026-10-07: 0 catalysts2026-10-08: 2 catalysts2026-10-09: 0 catalysts2026-10-10: 0 catalysts2026-10-11: 0 catalysts2026-10-12: 0 catalysts2026-10-13: 1 catalyst2026-10-14: 1 catalyst2026-10-15: 0 catalysts2026-10-16: 0 catalysts2026-10-17: 0 catalysts2026-10-18: 0 catalysts2026-10-19: 1 catalyst2026-10-20: 2 catalysts2026-10-21: 2 catalysts2026-10-22: 2 catalysts2026-10-23: 1 catalyst2026-10-24: 0 catalysts2026-10-25: 0 catalysts2026-10-26: 1 catalyst2026-10-27: 8 catalysts2026-10-28: 12 catalysts2026-10-29: 21 catalysts2026-10-30: 4 catalysts2026-10-31: 0 catalysts2026-11-01: 0 catalysts2026-11-02: 9 catalysts2026-11-03: 18 catalysts2026-11-04: 22 catalysts2026-11-05: 37 catalysts2026-11-06: 2 catalysts2026-11-07: 0 catalysts2026-11-08: 0 catalysts2026-11-09: 1 catalyst2026-11-10: 0 catalysts2026-11-11: 0 catalysts2026-11-12: 0 catalysts2026-11-13: 0 catalysts2026-11-14: 0 catalysts2026-11-15: 0 catalysts2026-11-16: 0 catalysts2026-11-17: 0 catalysts2026-11-18: 0 catalysts2026-11-19: 0 catalysts2026-11-20: 0 catalysts2026-11-21: 0 catalysts2026-11-22: 0 catalysts
view
agendamonth
sort
soonestlatesttypesponsoralpha
type: recall×type: approval×from 2026-01-26×clear all
type
  • 8k filing3,603
  • grant2,042
  • device adverse event1,000
  • approval955
  • device 510k696
  • earnings585
device pma
521
  • device recall231
  • phase 2 completion172
  • recall171
  • therapy area

    no tagged catalysts yet

    Week of Jan 26, 2026

    50
    ›Jan 26, 2026approval215d agoAMLODIPINE BESYLATE — FDA approvalGraviti Pharmaceuticals Inc

    Sponsor: GRAVITI PHARMS. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›Jan 26, 2026approval215d agoBETAMETHASONE DIPROPIONATE — FDA approvalBETAMETHASONE DIPROPIONATE

    Sponsor: AUROBINDO PHARMA LTD. Form: CREAM. Route: TOPICAL

    full page →BETAMETHASONE DIPROPIONATE →fda approvals ↗
    ›Jan 26, 2026approval215d agoPALIPERIDONE — FDA approvalpaliperidone ER

    Sponsor: APOTEX. Form: TABLET, EXTENDED RELEASE. Route: ORAL

    full page →paliperidone ER →fda approvals ↗
    ›Jan 26, 2026approval215d agoMETHYLPREDNISOLONE ACETATE — FDA approvalPFIZER INC

    Sponsor: CAPLIN. Form: INJECTABLE. Route: INJECTION

    full page →fda approvals ↗
    ›Jan 26, 2026approval215d agoDOXYCYCLINE HYCLATE — FDA approvalDOXYCYCLINE HYCLATE

    Sponsor: AMNEAL. Form: TABLET. Route: ORAL

    full page →DOXYCYCLINE HYCLATE →fda approvals ↗
    ›Jan 26, 2026approval215d agoFINASTERIDE — FDA approvalTeva Pharmaceuticals USA Inc

    Sponsor: TEVA. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›Jan 26, 2026approval215d agoCHLORPROMAZINE HYDROCHLORIDE — FDA approvalCHLORPROMAZINE HYDROCHLORIDE

    Sponsor: MSN. Form: INJECTABLE. Route: INJECTION

    full page →CHLORPROMAZINE HYDROCHLORIDE →fda approvals ↗
    ›Jan 26, 2026approval215d agoTRANEXAMIC ACID — FDA approvalHyloris Pharmaceuticals SA

    Sponsor: I 3 PHARMS. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›Jan 26, 2026approval215d agoDIFLUPREDNATE — FDA approvalDIFLUPREDNATE

    Sponsor: ALEMBIC. Form: EMULSION. Route: OPHTHALMIC

    full page →DIFLUPREDNATE →fda approvals ↗
    ›Jan 26, 2026approval215d agoTAPENTADOL HYDROCHLORIDE — FDA approvaltapentadol hydrochloride ER

    Sponsor: NOVITIUM PHARMA. Form: SOLUTION. Route: ORAL

    full page →tapentadol hydrochloride ER →fda approvals ↗
    ›Jan 26, 2026approval215d agoDAPTOMYCIN — FDA approvalDaptomycin Novo

    Sponsor: ACCORD HLTHCARE. Form: POWDER. Route: INTRAVENOUS

    full page →Daptomycin Novo →fda approvals ↗
    ›Jan 26, 2026approval215d agoBUDESONIDE — FDA approvalbudesonide DR

    Sponsor: RISING. Form: CAPSULE, DELAYED RELEASE. Route: ORAL

    full page →budesonide DR →fda approvals ↗
    ›Jan 26, 2026approval215d agoQUIOFIC (FOLIC ACID) — FDA approvalfolic acid

    Sponsor: SOLUBIOMIX. Form: SOLUTION. Route: ORAL

    full page →folic acid →fda approvals ↗
    ›Jan 26, 2026approval215d agoCUPRIC CHLORIDE — FDA approvalCUPRIC CHLORIDE

    Sponsor: AMNEAL. Form: INJECTABLE. Route: INJECTION

    full page →CUPRIC CHLORIDE →fda approvals ↗
    ›Jan 27, 2026approval214d agoDARZALEX FASPRO (DARATUMUMAB AND HYALURONIDASE-FIHJ) — FDA approval(daratumumab + hyaluronidase (human recombinant))

    Sponsor: JANSSEN BIOTECH. Form: INJECTABLE. Route: INJECTION

    full page →(daratumumab + hyaluronidase (human recombinant)) →fda approvals ↗
    ›Jan 27, 2026approval214d agoNOXAFIL POWDERMIX KIT (POSACONAZOLE) — FDA approvalPOSACONAZOLE

    Sponsor: MSD MERCK CO. Form: FOR SUSPENSION, DELAYED RELEASE. Route: ORAL

    full page →POSACONAZOLE →fda approvals ↗
    ›Jan 27, 2026approval214d agoTAPENTADOL HYDROCHLORIDE — FDA approvalCOLLEGIUM PHARMACEUTICAL, INC

    Sponsor: HUMANWELL. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›Jan 27, 2026approval214d agoNOXAFIL (POSACONAZOLE) — FDA approvalPOSACONAZOLE

    Sponsor: MERCK SHARP DOHME. Form: SOLUTION. Route: INTRAVENOUS

    full page →POSACONAZOLE →fda approvals ↗
    ›Jan 27, 2026approval214d agoFIDAXOMICIN — FDA approvalDificid

    Sponsor: TORRENT. Form: TABLET. Route: ORAL

    full page →Dificid →fda approvals ↗
    ›Jan 27, 2026approval214d agoVYXEOS (CYTARABINE) — FDA approvalMeitheal Pharmaceuticals Inc

    Sponsor: JAZZ PHARMS THERAP. Form: POWDER. Route: INTRAVENOUS

    full page →fda approvals ↗
    ›Jan 27, 2026approval214d agoMESNA — FDA approvalRiconpharma LLC

    Sponsor: EUGIA PHARMA. Form: INJECTABLE. Route: INTRAVENOUS

    full page →fda approvals ↗
    ›Jan 27, 2026approval214d agoTOPIRAMATE — FDA approvaltopiramate ER

    Sponsor: NATCO. Form: TABLET. Route: ORAL

    full page →topiramate ER →fda approvals ↗
    ›Jan 27, 2026approval214d agoPROPRANOLOL HYDROCHLORIDE — FDA approvalpropranolol hydrochloride ER

    Sponsor: MANKIND PHARMA. Form: TABLET. Route: ORAL

    full page →propranolol hydrochloride ER →fda approvals ↗
    ›Jan 27, 2026approval214d agoIDOSE TR (TRAVOPROST) — FDA approvalTRAVOPROST

    Sponsor: GLAUKOS. Form: IMPLANT. Route: INTRACAMERAL

    full page →TRAVOPROST →fda approvals ↗
    ›Jan 27, 2026approval214d agoIDOSE TR (TRAVOPROST) — FDA approvalTRAVOPROST

    Sponsor: GLAUKOS. Form: IMPLANT. Route: INTRACAMERAL

    full page →TRAVOPROST →fda approvals ↗
    ›Jan 27, 2026approval214d agoNOXAFIL (POSACONAZOLE) — FDA approvali3 Pharmaceuticals LLC

    Sponsor: SCHERING. Form: SUSPENSION. Route: ORAL

    full page →fda approvals ↗
    ›Jan 27, 2026approval214d agoCAPECITABINE — FDA approvalArmas Pharmaceuticals Inc

    Sponsor: ALKEM LABS LTD. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›Jan 27, 2026approval214d agoCAPRELSA (VANDETANIB) — FDA approvalvandetanib

    Sponsor: GENZYME CORP. Form: TABLET. Route: ORAL

    full page →vandetanib →fda approvals ↗
    ›Jan 27, 2026approval214d agoPRIFTIN (RIFAPENTINE) — FDA approvalrifapentine

    Sponsor: SANOFI AVENTIS US. Form: TABLET. Route: ORAL

    full page →rifapentine →fda approvals ↗
    ›Jan 27, 2026approval214d agoAMPICILLIN AND SULBACTAM (AMPICILLIN SODIUM) — FDA approvalUNASYN

    Sponsor: SANDOZ. Form: INJECTABLE. Route: INJECTION

    full page →UNASYN →fda approvals ↗
    ›Jan 27, 2026approval214d agoDEFLAZACORT — FDA approvalAmneal Pharmaceuticals, Inc.

    Sponsor: SUN PHARM INDS INC. Form: SUSPENSION. Route: ORAL

    full page →fda approvals ↗
    ›Jan 27, 2026approval214d agoNOXAFIL (POSACONAZOLE) — FDA approvalPOSACONAZOLE

    Sponsor: MERCK SHARP DOHME. Form: TABLET, DELAYED RELEASE. Route: ORAL

    full page →POSACONAZOLE →fda approvals ↗
    ›Jan 28, 2026approval213d agoVFEND (VORICONAZOLE) — FDA approvalGreenstone LLC

    Sponsor: PF PRISM CV. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›Jan 28, 2026approval213d agoVFEND (VORICONAZOLE) — FDA approvalGreenstone LLC

    Sponsor: PF PRISM CV. Form: POWDER. Route: INTRAVENOUS

    full page →fda approvals ↗
    ›Jan 28, 2026approval213d agoVFEND (VORICONAZOLE) — FDA approvalGreenstone LLC

    Sponsor: PF PRISM CV. Form: FOR SUSPENSION. Route: ORAL

    full page →fda approvals ↗
    ›Jan 28, 2026approval213d agoALENDRONATE SODIUM — FDA approvalALENDRONATE SODIUM

    Sponsor: HIKMA. Form: SOLUTION. Route: ORAL

    full page →ALENDRONATE SODIUM →fda approvals ↗
    ›Jan 28, 2026approval213d agoALENDRONATE SODIUM — FDA approvalALENDRONATE SODIUM

    Sponsor: HIKMA. Form: SOLUTION. Route: ORAL

    full page →ALENDRONATE SODIUM →fda approvals ↗
    ›Jan 28, 2026approval213d agoYUVEZZI (BRIMONIDINE TARTRATE) — FDA approvalBausch & Lomb Corp

    Sponsor: VISUS. Form: SOLUTION/DROPS. Route: OPHTHALMIC

    full page →fda approvals ↗
    ›Jan 28, 2026approval213d agoDAYSEE (ETHINYL ESTRADIOL) — FDA approvalNORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

    Sponsor: LUPIN LTD. Form: TABLET. Route: ORAL

    full page →NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE →fda approvals ↗
    ›Jan 28, 2026approval213d agoISOSULFAN BLUE — FDA approvalISOSULFAN BLUE

    Sponsor: MYLAN INSTITUTIONAL. Form: SOLUTION. Route: SUBCUTANEOUS

    full page →ISOSULFAN BLUE →fda approvals ↗
    ›Jan 28, 2026approval213d agoCLOMIPRAMINE HYDROCHLORIDE — FDA approvalTruPharma LLC

    Sponsor: TARO. Form: CAPSULE. Route: ORAL

    full page →fda approvals ↗
    ›Jan 28, 2026approval213d agoABILIFY MAINTENA KIT (ARIPIPRAZOLE) — FDA approvalaripiprazole LA

    Sponsor: OTSUKA PHARM CO LTD. Form: FOR SUSPENSION, EXTENDED RELEASE. Route: INTRAMUSCULAR

    full page →aripiprazole LA →fda approvals ↗
    ›Jan 28, 2026approval213d agoSERTRALINE HYDROCHLORIDE — FDA approvalSERTRALINE HYDROCHLORIDE

    Sponsor: AMNEAL. Form: CAPSULE. Route: ORAL

    full page →SERTRALINE HYDROCHLORIDE →fda approvals ↗
    ›Jan 28, 2026approval213d agoDIVALPROEX SODIUM — FDA approvalUnichem Pharmaceuticals (USA) Inc

    Sponsor: UNICHEM. Form: TABLET, EXTENDED RELEASE. Route: ORAL

    full page →fda approvals ↗
    ›Jan 28, 2026approval213d agoDIVALPROEX SODIUM — FDA approvalUnichem Pharmaceuticals (USA) Inc

    Sponsor: UNICHEM. Form: TABLET, EXTENDED RELEASE. Route: ORAL

    full page →fda approvals ↗
    ›Jan 28, 2026recall213d agoCipla USA, Inc. recall (Cls III)Cipla USA Inc

    Diclofenac Sodium Topical Gel, 1%, NET WT 100 g (3.53 oz), Manufactured by: DPT Laboratories, Ltd., 307 E Josephine Street, San Antonio, TX 78215. NDC: 76282-103-39 — Reason: Failed PH Specifications — Status: Ongoing

    full page →fda recalls ↗
    ›Jan 28, 2026recall213d agoZydus Pharmaceuticals (USA) Inc recall (Cls II)LB PHARMACEUTICALS INC

    Icosapent Ethyl capsules, 1 gram, 120-count bottles, Rx only, Manufactured by: Softgel Healthcare Pvt. Ltd., India, Distributed by: Zydus Pharmaceuticals (USA) Inc., Pennington, NJ 08534, NDC 70710-1592-07 — Reason: Subpotent Drug: Due oxidation caused by leakage of the contents of the Icosapent Ethyl 1g capsules. Use of the affected product may lead to inconsistent therapeutic effects and an increase in potential gastrointestinal side effects in some patients. — Status: Ongoing

    full page →fda recalls ↗
    ›Jan 28, 2026recall213d agoGraviti Pharmaceuticals Private Limited recall (Cls II)Graviti Pharmaceuticals Inc

    Furosemide Tablets, USP 40 mg, 1,000 Tablets, Rx Only, Manufactured for: Rising Pharmaceuticals Inc., East Brunswick, NJ 08816, Manufactured by: Graviti Pharmaceuticals Pvt. Ltd. Telangana - 502307, India, NDC 64980-563-10. — Reason: Presence of Foreign Substance — Status: Ongoing

    full page →fda recalls ↗
    ›Jan 28, 2026recall213d agoSpecialty Process Labs LLC recall (Cls II)

    Thyroid, USP, Rx only, Net Wt: 0.50kg, For Manufacturing, Processing or Repackaging Use Only, Specialty Process Labs, Phoenix, AZ 85034, NDC 81305-100-02 — Reason: Subpotent Drug — Status: Ongoing

    full page →fda recalls ↗
    ›Jan 29, 2026approval212d agoWEGOVY (SEMAGLUTIDE) — FDA approvalNovo Nordisk AS

    Sponsor: NOVO. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ← prev
    page 1 of 23
    next →
    $PFE28.03-0.96%
    $COLL26.44-3.89%
    $MRK153.10-2.14%
    $AMRX17.54-2.61%
    $GKOS181.91+0.74%
    $GKOS181.91+0.74%
    $AMRX17.54-2.61%
    $AMRX17.54-2.61%
    $BLCO17.13-0.70%
    $AMRX17.54-2.61%
    $LBRX47.73-0.33%